Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.92 Insider Own68.79% Shs Outstand37.23M Perf Week26.00%
Market Cap503.80M Forward P/E- EPS next Y- Insider Trans1.03% Shs Float17.04M Perf Month109.13%
Income-39.47M PEG- EPS next Q- Inst Own7.07% Short Float / Ratio13.70% / 13.87 Perf Quarter96.57%
Sales-0.01M P/S- EPS this Y- Inst Trans-15.53% Short Interest2.33M Perf Half Y43.12%
Book/sh0.95 P/B9.66 EPS next Y- ROA-51.43% Target Price5.00 Perf Year358.00%
Cash/sh0.92 P/C10.00 EPS next 5Y- ROE-135.34% 52W Range1.85 - 10.21 Perf YTD230.69%
Dividend- P/FCF- EPS past 5Y0.07% ROI-65.23% 52W High-10.28% Beta1.65
Dividend %- Quick Ratio9.50 Sales past 5Y-10.13% Gross Margin-4734.38% 52W Low395.14% ATR0.75
Employees61 Current Ratio9.50 Sales Q/Q- Oper. Margin442066.67% RSI (14)80.95 Volatility14.92% 12.45%
OptionableYes Debt/Eq0.18 EPS Q/Q60.37% Profit Margin438600.00% Rel Volume2.04 Prev Close9.03
ShortableYes LT Debt/Eq0.16 EarningsNov 13 BMO Payout- Avg Volume168.28K Price9.16
Recom3.00 SMA2043.76% SMA5081.65% SMA20066.13% Volume342,806 Change1.44%
Date Action Analyst Rating Change Price Target Change
Jul-27-21Initiated Stephens Overweight $28
Mar-11-21Initiated Maxim Group Buy $40
Jan-26-21Reiterated H.C. Wainwright Buy $16 → $40
May-12-20Upgrade H.C. Wainwright Neutral → Buy $6 → $16
Feb-14-20Downgrade H.C. Wainwright Buy → Neutral $26 → $6
Feb-25-19Initiated H.C. Wainwright Buy $27
Nov-21-23 08:00AM
Nov-15-23 04:05PM
Nov-14-23 12:52PM
Nov-13-23 11:13AM
08:00AM Loading…
Nov-10-23 04:56PM
Oct-30-23 04:05PM
Oct-24-23 08:00AM
Oct-02-23 08:00AM
Sep-29-23 08:00AM
Sep-27-23 08:00AM
Sep-07-23 04:05PM
Aug-24-23 04:05PM
Aug-17-23 09:31AM
06:28AM Loading…
Aug-11-23 06:28AM
Aug-10-23 04:05PM
Jul-30-23 09:35AM
Jul-27-23 04:05PM
May-22-23 09:30AM
May-18-23 07:00AM
May-16-23 12:01PM
May-12-23 07:43AM
May-11-23 04:05PM
May-10-23 09:29AM
May-03-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:05PM
Apr-20-23 06:04AM
Apr-05-23 07:46PM
04:05PM Loading…
Mar-30-23 04:05PM
Mar-10-23 08:30AM
Mar-02-23 04:05PM
Feb-02-23 08:00AM
Dec-10-22 07:24AM
Nov-10-22 04:05PM
Oct-27-22 04:05PM
Oct-14-22 06:17AM
Oct-06-22 08:00AM
Oct-01-22 08:50AM
Sep-26-22 10:00AM
Sep-21-22 10:03AM
Sep-20-22 04:26PM
Aug-10-22 05:25PM
Aug-04-22 08:00AM
Jul-27-22 04:05PM
Jun-16-22 04:15PM
Jun-09-22 04:43PM
Jun-03-22 08:00AM
May-19-22 08:00AM
May-13-22 01:44PM
May-11-22 06:05PM
May-04-22 08:00AM
Apr-28-22 08:00AM
Apr-26-22 08:00AM
Apr-14-22 04:05PM
Mar-31-22 05:25PM
Mar-21-22 04:05PM
Mar-17-22 06:57AM
Feb-15-22 08:00AM
Feb-08-22 12:37PM
Feb-01-22 04:05PM
Jan-11-22 07:00AM
Dec-28-21 02:38AM
Dec-17-21 09:20AM
Nov-25-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
Nov-04-21 04:05PM
Nov-02-21 04:05PM
Oct-05-21 08:00AM
Sep-02-21 04:05PM
Aug-19-21 04:05PM
Aug-09-21 04:05PM
Jul-26-21 04:05PM
Jul-06-21 01:34AM
Jul-01-21 05:45PM
Jun-30-21 10:56AM
Jun-11-21 06:17AM
Jun-09-21 09:05AM
May-24-21 08:00AM
May-13-21 09:16AM
May-11-21 07:17AM
May-10-21 04:05PM
Apr-26-21 04:05PM
Apr-22-21 08:00AM
Mar-12-21 03:19AM
Mar-05-21 08:00AM
Feb-22-21 04:05PM
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUGGAN ROBERT WDirectorNov 29Option Exercise5.951,6679,91936,392,861Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 29Buy9.44158,6001,497,18436,551,461Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 29Buy9.2160,000552,60060,000Dec 01 07:36 PM
DUGGAN ROBERT WDirectorNov 28Buy8.98124,3971,117,08536,391,194Nov 30 07:25 PM
DUGGAN ROBERT WDirectorNov 17Buy6.1020,241123,47036,266,797Nov 20 08:56 PM
Danahy Kevin PatrickChief Executive OfficerNov 16Buy6.525,39335,15635,887Nov 17 09:11 AM
Levinson Mitchell E.Chief Strategy OfficerNov 15Buy5.9113,53980,0589,135Nov 17 09:10 AM
Levinson Mitchell E.Chief Strategy OfficerNov 15Buy5.874,26125,03373,027Nov 17 09:10 AM
Zanganeh MahkamDirectorNov 13Option Exercise2.1476,075162,800604,911Nov 15 05:37 PM
DUGGAN ROBERT WDirectorNov 07Option Exercise5.9513,26578,92736,246,556Nov 09 06:32 PM
DUGGAN ROBERT WDirectorAug 25Option Exercise5.951,6679,91936,233,291Aug 28 08:08 PM
DUGGAN ROBERT WDirectorJul 25Option Exercise5.951,6679,91936,231,624Jul 27 09:09 AM
DUGGAN ROBERT WDirectorJul 07Option Exercise2.2367,133150,01236,229,957Jul 07 06:26 PM
DUGGAN ROBERT WDirectorJul 05Option Exercise2.1465,000139,10036,162,824Jul 07 06:26 PM
DUGGAN ROBERT WDirectorMay 09Buy6.5110,022,93765,249,32030,414,661May 10 05:41 PM